Abstract:Key PointsObesity is a chronic, debilitating disease with devastating overall health effects and a global burden of disease; weight loss can improve these outcomesAnti-obesity drugs should be initiated promptly when appropriate criteria are met if a patient fails self-directed or professionally directed lifestyle treatmentAnti-obesity drugs are approved in patients with a BMI ≥27 kg/m2 with at least one obesity-related comorbidity such as diabetes mellitus, hypertension, hyperlipidaemia or sleep apnoea or in patients with a BMI ≥30 kg/m2Currently, six major FDA-approved anti-obesity medications are available: phentermine, orlistat, phentermine/topiramate extended release (ER), lorcaserin, naltrexone sustained release (SR)/bupropion SR and liraglutide (the only injectable formulation)Most of these anti-obesity drugs have an efficacy of 3–7% (estimated net weight loss)Identifying the type of obesity on clinical presentation coupled with an understanding of anti-obesity drug safety, contraindications and adverse effect profiles can selectively increase weight loss through appropriate use of these drugs

Current pharmacotherapy for obesity